Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. META

Go back to Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Acadia Pharma (ACAD) Misses Q4 EPS by 3c

February 28, 2022 4:05 PM EST

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $130.76 million versus the consensus estimate of $135.6 million.

GUIANCE:

2022 Financial Guidance

NUPLAZID net sales guidance in Parkinsons... More